Minster Pharmaceuticals plc (AIM: MPM), the drug development company specialising in neurological and psychiatric disorders, is pleased to announce that Professor Peter Goadsby, the principal investigator in the Company’s recent clinical trial of tonabersat in the prevention of migraine, will deliver a presentation at the 49th Annual Scientific Meeting of the American Headache Society on Saturday 9 June 2007 in Chicago, Illinois. The presentation by Prof Goadsby, who is Professor of Neurology at the Institute of Neurology in London, will form part of a prestigious late-breaking session. The presentation will focus on the positive trial data from a Phase IIa study of tonabersat in the prevention of migraine, the initial findings from which were announced earlier this year.
Further details about the American Headache Society meeting are available from the organisations website: www.americanheadachessociety.org